186 related articles for article (PubMed ID: 37481734)
21. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
22. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
23. Ultra-efficient delivery of CRISPR/Cas9 using ionic liquid conjugated polymers for genome editing-based tumor therapy.
Huang Z; Yang T; Yu J; Gao Y; Weng Y; Huang Y; Li S
Biomater Sci; 2024 Mar; 12(7):1716-1725. PubMed ID: 38344762
[TBL] [Abstract][Full Text] [Related]
24. PAR2 deficiency tunes inflammatory microenvironment to magnify STING signalling for mitigating cancer metastasis via anionic CRISPR/Cas9 nanoparticles.
Fu X; Li J; Wu Y; Mao C; Jiang Y
J Control Release; 2023 Nov; 363():733-746. PubMed ID: 37827223
[TBL] [Abstract][Full Text] [Related]
25. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
26. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
Ma T; Chen X; Wang M
Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
[TBL] [Abstract][Full Text] [Related]
27. Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles.
Luo YL; Xu CF; Li HJ; Cao ZT; Liu J; Wang JL; Du XJ; Yang XZ; Gu Z; Wang J
ACS Nano; 2018 Feb; 12(2):994-1005. PubMed ID: 29314827
[TBL] [Abstract][Full Text] [Related]
28. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy.
Zou Y; Sun X; Yang Q; Zheng M; Shimoni O; Ruan W; Wang Y; Zhang D; Yin J; Huang X; Tao W; Park JB; Liang XJ; Leong KW; Shi B
Sci Adv; 2022 Apr; 8(16):eabm8011. PubMed ID: 35442747
[TBL] [Abstract][Full Text] [Related]
29. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.
Han JP; Kim M; Choi BS; Lee JH; Lee GS; Jeong M; Lee Y; Kim EA; Oh HK; Go N; Lee H; Lee KJ; Kim UG; Lee JY; Kim S; Chang J; Lee H; Song DW; Yeom SC
Sci Adv; 2022 Jan; 8(3):eabj6901. PubMed ID: 35061543
[TBL] [Abstract][Full Text] [Related]
30. CRISPR/Cas9-Enabled Multiplex Genome Editing and Its Application.
Minkenberg B; Wheatley M; Yang Y
Prog Mol Biol Transl Sci; 2017; 149():111-132. PubMed ID: 28712493
[TBL] [Abstract][Full Text] [Related]
31. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
32. Synthetic nanoparticles for the delivery of CRISPR/Cas9 gene editing system: classification and biomedical applications.
Zheng Q; Wang W; Zhou Y; Mo J; Chang X; Zha Z; Zha L
Biomater Sci; 2023 Aug; 11(16):5361-5389. PubMed ID: 37381725
[TBL] [Abstract][Full Text] [Related]
33. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
34. Effects of sgRNAs, Promoters, and Explants on the Gene Editing Efficiency of the CRISPR/Cas9 System in Chinese Kale.
Huang W; Zheng A; Huang H; Chen Z; Ma J; Li X; Liang Q; Li L; Liu R; Huang Z; Qin Y; Tang Y; Li H; Zhang F; Wang Q; Sun B
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686051
[TBL] [Abstract][Full Text] [Related]
35. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
Cai W; Luo T; Mao L; Wang M
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
[TBL] [Abstract][Full Text] [Related]
36. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
37. A DNA Origami-Based Gene Editing System for Efficient Gene Therapy in Vivo.
Tang W; Tong T; Wang H; Lu X; Yang C; Wu Y; Wang Y; Liu J; Ding B
Angew Chem Int Ed Engl; 2023 Dec; 62(51):e202315093. PubMed ID: 37906116
[TBL] [Abstract][Full Text] [Related]
38. Redox-Responsive Phase-Separating Peptide as a Universal Delivery Vehicle for CRISPR/Cas9 Genome Editing Machinery.
Sun Y; Xu X; Chen L; Chew WL; Ping Y; Miserez A
ACS Nano; 2023 Sep; 17(17):16597-16606. PubMed ID: 37584415
[TBL] [Abstract][Full Text] [Related]
39. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
[TBL] [Abstract][Full Text] [Related]
40. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
